|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 201.18 USD | +8.53% |
|
+11.84% | +14.31% |
| 02-06 | Stifel Nicolaus Adjusts Biogen PT to $214 From $202, Maintains Buy Rating | MT |
| 02-06 | Biogen Inc., Q4 2025 Earnings Call, Feb 06, 2026 |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Novel Therapeutics for Human Health Care | - | - | - | - | - | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
Biological Products | ||||||||||
Discovering, Developing and Delivering Innovative Therapies | 10.98B | 10.17B | 9.84B | 9.68B | - | |||||
Total Assets | 23.88B | 24.55B | 26.84B | 28.05B | - | |||||
Interest Expense | -254M | -247M | -247M | -250M | - | |||||
Income Tax Expense | 52.5M | 633M | 135M | 274M | - | |||||
CAPEX | -258M | -243M | -277M | -154M | - | |||||
EBT | 1.75B | 3.59B | 1.3B | 1.91B | - | |||||
D&A | 488M | 518M | 495M | 673M | - | |||||
Operating Income | 2.84B | - | - | - | - | |||||
Net Income | 1.56B | 3.05B | 1.16B | 1.63B | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Europe (Incl. Germany) | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
Germany | 1.16B | 926M | 868M | 956M | - | |||||
Total Assets | 25.4M | 21M | 17.5M | 13.3M | - | |||||
Europe | 2.64B | 2.41B | 2.14B | 2.17B | - | |||||
Total Assets | 2.34B | 2.28B | 2.25B | 2.14B | - | |||||
Asia | 725M | 720M | 863M | 624M | - | |||||
Total Assets | 16.4M | 13.7M | 8.3M | 8.5M | - | |||||
Other | 627M | 583M | 531M | 558M | - | |||||
Total Assets | 21.7M | 22.6M | 12.9M | 10.6M | - | |||||
United States (U.S.) | 5.83B | 5.53B | 5.43B | 5.31B | - | |||||
Total Assets | 1.39B | 1.37B | 1.44B | 1.37B | - |
- Stock Market
- Equities
- BIIB Stock
- Financials Biogen Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition